MRTX - FDA AdCom Gives Thumbs Down To Late-Stage Data For Amgen's Lumakras In Advanced Form Of Lung Cancer (UPDATED) | Benzinga
Editor's note: The headline of this story has been updated to make clearer the FDA vote is on late-stage Lumakras data.
FDA advisers concluded that the data from a late-stage trial lacks the requisite reliability to endorse the traditional approval of Amgen Inc's (NASDAQ: AMGN) Lumakras for patients afflicted with an advanced form of lung cancer.
During the meeting, the FDA's expert advisers Full story available on Benzinga.com